Digital Twins Emerge as Breakthrough in Rare Disease Research, Certara's Piet van der Graaf Explains
核心洞察
Over 7,000 rare diseases (搜索) affect an estimated 30 million people in the US alone, yet these conditions have long been underfunded and under-researched, leaving patients with limited therapeutic options.
Virtual trials utilizing digital twin technology are emerging as a breakthrough approach in rare disease research and drug development.
Piet van der Graaf, Senior VP at Certara, discusses how predictive simulation, data-driven modeling, and AI are being tailored to advance rare disease drug development.
The landscape of rare disease research is undergoing a transformative shift as virtual trials and digital twin technologies gain traction. In a recent pharmaphorum podcast, web editor Nicole Raleigh spoke with Piet van der Graaf, Senior Vice President at Certara, about the potential of digital twins to reshape drug development for rare diseases (搜索).
With over 7,000 rare diseases (搜索) affecting an estimated 30 million people in the United States alone, these conditions have historically suffered from chronic underfunding and insufficient research attention. The result has been a persistent gap in therapeutic options for patients who face these often devastating diagnoses.
Certara, a company specializing in predictive simulation, data-driven modeling, and artificial intelligence tailored for drug development, is at the forefront of applying digital twin technology to this challenge. Digital twins — virtual representations of patients built from biological and clinical data — allow researchers to simulate disease progression and treatment responses without requiring large patient cohorts that are often impossible to assemble for rare conditions.
Van der Graaf's insights highlight how computational approaches are increasingly being leveraged to overcome the inherent challenges of rare disease trials, where small patient populations make traditional randomized controlled trials difficult or infeasible. By creating virtual patient models, researchers can explore therapeutic hypotheses, optimize trial designs, and potentially accelerate the path from discovery to regulatory submission.
The conversation underscores a broader industry trend: the convergence of advanced computational modeling with clinical development, particularly in therapeutic areas where conventional approaches have fallen short. As virtual trials continue to evolve, they may offer a viable pathway to bring new therapies to the millions of patients living with rare diseases (搜索) who currently have few, if any, treatment options.